Imagine using a specialized 'cleanup crew' of plants, worms, and tiny microbes to scrub toxins out of the earth. Instead of just using one type of bacteria, this project builds a team of different organisms that work together to eat pollutants. It's like upgrading from a single broom to a professional cleaning service for the planet's most polluted spots.
Traditional cleanup methods using single microbes often fail in real-world settings because pollution is too complex. This leads to expensive, incomplete remediation of industrial and agricultural lands.
A system of combined biologics (enzymes, microbes, plants, worms) and platform technologies like 3D-printing for biodegrader distribution and genomic editing for enzyme production.
If you are a redevelopment firm dealing with old industrial sites polluted by petroleum and chlorinated hydrocarbons — this project developed system-based bioremediation that targets at least 90% removal of these pollutants. This allows for faster land recovery and restoration of ecological status.
If you are a farm operator dealing with soil contaminated by plastics and pesticides — this project developed a combination of microbes and plants that can detoxify the land. This helps restore soil health and biodiversity to meet strict environmental specifications.
If you are a utility provider dealing with emerging micropollutants like pharmaceuticals and microplastics in wastewater — this project developed a system of enzymes and microorganisms to degrade these substances. This ensures treated water meets higher safety and environmental standards.
Based on available project data, the project performs life cycle cost and cost-efficiency analysis to benchmark these solutions against current options, but specific pricing is not provided.
Yes, the project includes validation at pilot and field scale across 4 real contaminated sites to ensure the strategies work in real-world environments.
Based on available project data, there is no specific mention of licensing terms, though the project involves 7 industry partners and 4 SMEs who may hold joint IP.
The project specifically includes a biosafety and regulatory constraints analysis to ensure the systems, including genomically edited biologics, are compliant.
Based on available project data, the project runs from 2023 to 2026, but the specific degradation timeline for pollutants at the sites is not listed.
The consortium is highly balanced for commercialization, featuring 18 partners across 12 countries. With a 39% industry ratio (7 companies, including 4 SMEs), there is a strong bridge between the 7 universities and 3 research centers and the actual market, suggesting the results are being developed with commercial viability in mind.
Contact the University of Bologna (ALMA MATER STUDIORUM) research office.
Contact us to connect with the NYMPHE consortium for pilot licensing.
